Loading...
•
Jun 30
MeiraGTx Q2 2025 Earnings Report
MeiraGTx reported a narrowed quarterly loss with increased service revenue driven by clinical manufacturing services.
Key Takeaways
MeiraGTx posted $3.7M in service revenue for Q2 2025, significantly up from $0.3M YoY, while narrowing its net loss to $38.8M. The company ended the quarter with $32.2M in cash and cash equivalents and continues to advance multiple late-stage programs and regulatory filings.
Service revenue rose to $3.7M, driven by PPQ services for Johnson & Johnson Innovative Medicine
Net loss narrowed to $38.8M from $48.6M YoY
Cash and cash equivalents stood at $32.2M at quarter-end
Weighted average shares outstanding increased to 80.6M from 64.4M YoY
MeiraGTx
MeiraGTx
MeiraGTx Revenue by Segment
Revenue by Segment
Service Revenue
CapyFin.com Forward Guidance
MeiraGTx expects to initiate several clinical trials and regulatory filings by year-end 2025, supported by strategic partnerships and internal manufacturing capabilities.
Positive Outlook
- RMAT designation granted for AAV-GAD in Parkinson’s disease
- FDA alignment for pivotal AAV-AQP1 study in radiation-induced xerostomia
- Strong collaboration and funding from Hologen for CNS gene therapies
- Manufacturing capability recognized in U.K. and Ireland inspections
- Advancement of riboswitch platform for in vivo delivery into human trials
Challenges Ahead
- Continued operating and net losses
- High R&D and G&A expenses maintained
- Share dilution from increased outstanding shares
- No license revenue recognized in the quarter
- Ongoing reliance on external funding and milestones